COVID-19 Resources: More details
ImmuniMed Inc. is an innovative, clinical-stage, Research & Development Biopharmaceutical Company. ImmuniMed Inc. develops oral antibody therapy using passive vaccination to treat and prevent gastro-enteric infections. Their technology is designed to utilize chicken eggs as bioreactors to manufacture specific polyclonal antibodies – a new class of biopharmaceuticals.
member
Through the Manitoba Works Capital Incentive, the Manitoba government will provide a rebate of up to $4.2 million over a maximum of 20 years to a commercial greenhouse development in the Parkland region, Minister Eichler announced
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.